CTNI-18. FINAL RESULTS OF A PHASE 2 STUDY OF EFFICACY, SAFETY AND INTRATUMORAL PHARMACOKINETICS (PK) OF SELINEXOR MONOTHERAPY IN RECURRENT GLIOBLASTOMA (rGBM)

BACKGROUND: Selinexor is an FDA-approved first-in-class, oral selective nuclear export inhibitor which forces nuclear retention of many tumor suppressor proteins. METHODS: We conducted a phase 2 trial of selinexor monotherapy for adults with recurrent GBM including a surgical arm to explore intratum...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Lassman, Andrew, Wen, Patrick, van den Bent, Martin, Plotkin, Scott, Walenkamp, Annemiek, Green, Adam, Wang, Hongwei, Li, Kai, Liu, Yang, Xu, Hongmei, Shah, Jatin, Kauffman, Michael, Shacham, Sharon, Mau-Soerensen, Morten
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Trials: Non-Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650477/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.185
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados